Nuvectis Pharma (NVCT) Assets (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Assets data on file, last reported at $25.4 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 15.76% year-over-year to $25.4 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (down 15.76% YoY), and the FY2025 full-year result was $31.7 million, up 70.41% from the prior year.
• Assets eased to $25.4 million in Q1 2026, from $31.7 million in the prior quarter.
• In the past five years, Assets ranged from a high of $35.6 million in Q3 2025 to a low of $14.2 million in Q2 2022.
• A 5-year average of $22.6 million and a median of $20.4 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets jumped 206.52% in 2022 and fell 26.63% in 2024, its largest moves.
• Tracing NVCT's Assets over 5 years: stood at $20.4 million in 2022, then decreased by 5.98% to $19.2 million in 2023, then dropped by 3.01% to $18.6 million in 2024, then jumped by 70.41% to $31.7 million in 2025, then slipped by 19.9% to $25.4 million in 2026.
• Business Quant data shows NVCT's Assets at $25.4 million in Q1 2026, $31.7 million in Q4 2025, and $35.6 million in Q3 2025.